News & Updates

Faecal microbiota transplantation helps reduce abdominal bloating but not the overall symptoms in patients with irritable bowel syndrome (IBS), according to a small study.

In the phase II VELO trial, third-line (3L) treatment with the anti-EGFR* monoclonal antibody (mAb) panitumumab and standard of care (SoC) improved progression-free survival (PFS) in patients with refractory RAS wild-type metastatic colorectal cancer (WT mCRC).

Using 30 kcal/kg to predict energy requirements overestimates total energy expenditure (TEE) by 1.44 times in patients with colorectal cancer (CRC) in a controlled sedentary environment, as shown in a study. In addition, TEE is outside of the predicted requirement range for most.

In patients with HER-2-overexpressing metastatic or advanced gastric/gastroesophageal (G/GEJ) adenocarcinoma, a regimen comprising standard-of-care chemotherapy and a HER2-targeting peptide vaccine induced antibody responses that corresponded with tumour size reduction, according to an analysis of the HERIZON study which looked into the correlation between antibody responses and clinical outcomes.